Diversified Trust Co Reduces Stake in Cigna Corp (NYSE:CI)

Diversified Trust Co cut its stake in shares of Cigna Corp (NYSE:CI) by 3.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 3,437 shares of the health services provider’s stock after selling 130 shares during the quarter. Diversified Trust Co’s holdings in Cigna were worth $645,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Quarterback LLC bought a new stake in shares of Cigna in the fourth quarter worth about $12,552,310,000. Massachusetts Financial Services Co. MA boosted its position in shares of Cigna by 18.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 12,624,555 shares of the health services provider’s stock valued at $2,236,818,000 after buying an additional 1,926,123 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Cigna by 1.5% in the first quarter. Geode Capital Management LLC now owns 5,534,854 shares of the health services provider’s stock valued at $978,720,000 after purchasing an additional 79,936 shares during the period. Sanders Capital LLC boosted its holdings in shares of Cigna by 3.0% in the first quarter. Sanders Capital LLC now owns 5,478,701 shares of the health services provider’s stock valued at $1,102,182,000 after purchasing an additional 161,060 shares during the period. Finally, Macquarie Group Ltd. increased its position in shares of Cigna by 2.0% during the fourth quarter. Macquarie Group Ltd. now owns 4,955,559 shares of the health services provider’s stock worth $1,013,407,000 after purchasing an additional 95,094 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.

Several research firms recently issued reports on CI. Royal Bank of Canada upped their target price on Cigna from $249.00 to $266.00 and gave the company an “outperform” rating in a research report on Friday, May 1st. Deutsche Bank cut their price objective on shares of Cigna from $288.00 to $279.00 and set a “buy” rating for the company in a report on Monday, May 4th. UBS Group cut their price target on shares of Cigna from $252.00 to $246.00 and set a “buy” rating for the company in a report on Friday, June 5th. SVB Leerink began coverage on shares of Cigna in a report on Wednesday, July 1st. They issued a “market perform” rating and a $220.00 target price for the company. Finally, SunTrust Banks decreased their price target on shares of Cigna from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $244.62.

CI opened at $180.08 on Thursday. The company has a fifty day simple moving average of $193.79 and a 200 day simple moving average of $192.95. The firm has a market cap of $67.17 billion, a price-to-earnings ratio of 13.83, a PEG ratio of 0.89 and a beta of 0.70. Cigna Corp has a twelve month low of $118.50 and a twelve month high of $224.64. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 0.71.

Cigna (NYSE:CI) last released its quarterly earnings results on Thursday, April 30th. The health services provider reported $4.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.35 by $0.34. The business had revenue of $38.39 billion during the quarter, compared to analyst estimates of $37.09 billion. Cigna had a net margin of 3.19% and a return on equity of 15.05%. The business’s revenue was up 14.8% on a year-over-year basis. During the same period last year, the business earned $3.90 EPS. On average, analysts forecast that Cigna Corp will post 18.42 earnings per share for the current fiscal year.

In other Cigna news, Director William L. Roper sold 2,819 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $192.07, for a total transaction of $541,445.33. Following the transaction, the director now directly owns 10,442 shares in the company, valued at approximately $2,005,594.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Timothy C. Wentworth sold 2,200 shares of the stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $201.11, for a total transaction of $442,442.00. Following the completion of the sale, the insider now directly owns 70,943 shares in the company, valued at approximately $14,267,346.73. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 300,485 shares of company stock valued at $62,038,903. Company insiders own 0.90% of the company’s stock.

Cigna Profile

Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.

See Also: Investing strategies using the yield curve

Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corp (NYSE:CI).

Institutional Ownership by Quarter for Cigna (NYSE:CI)

Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.